Opinion 13 Jun 2023 How will European Commission proposals on data exclusivity and the bolar exemption affect pharma companies? By Andrew Sharples, co-head of EIP’s UK litigation team In April, the European Commission published proposed legislation (specifically a new Regulation and a new Directive) aimed at reforming EU legislation in relation to pharmaceuticals. These proposals, if adopted, will affect pharmaceutical regulation in several ways. In relation to IP specifically, they will affect the periods […] June 13, 2023 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Jun 2023 Six advancements in Alzheimer’s research over the past year The most common cause of dementia, Alzheimer’s disease, is a brain disorder that is characterized by cognitive decline which often manifests itself through memory loss, feelings of disorientation and difficulty making decisions. Alzheimer’s occurs when there is an excessive accumulation of proteins in the brain, a hallmark feature of the disease. These proteins, namely, amyloid […] June 12, 2023 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jun 2023 Beacon Therapeutics launches with $120M to develop gene therapies for retinal diseases Beacon Therapeutics Holdings Limited has been launched to develop gene therapies to treat a range of rare and prevalent retinal diseases that result in blindness. Syncona Limited, with additional investors including Oxford Science Enterprises, has provided £96 million ($120 million) to fund the acquisition of AGTC and provide capital to take Beacon Therapeutics’ development candidates […] June 12, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2023 Chronic myeloid leukemia: Novartis survey signals need for better patient-physician communication Only 19% to 26% of patients with chronic myeloid leukemia (CML) discuss treatment decisions with their physician, a survey by Swiss-based pharmaceutical Novartis has revealed. The Survey of Unmet Needs in CML (CML SUN), which investigated how patients and physicians felt about current treatment options, joint decision-making, and treatment satisfaction, also found that 39% to […] June 9, 2023 - 4 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 9 Jun 2023 Enhancing canine wellness: The promise of immunotherapy for dogs Given that dogs are widely regarded as ‘man’s best friend’, it makes sense that we are constantly striving to find ways to improve canine health and extend their lives. One method that has been – and is still being – explored is the use of immunotherapy, which uses a dog’s own immune system to fight […] June 9, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 9 Jun 2023Beyond Biotech podcast 49 This week, we have a conversation about precision medicine with Tero Silvola, CEO at BC Platforms. We also discuss the acquisition of 4Pharma. The acquisition expands BCP’s global service offering for accelerating the translation of innovations into clinical practice. In addition, 4Pharma customers will benefit from additional services in the field of RWD through the […] June 9, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2023 Med-Life Discoveries to start rare pediatric disease trial Med-Life Discoveries, LP (MLD) is a Canadian biopharmaceutical company dedicated to advancing a therapy to reduce symptoms for a devastating pediatric rare disease, Rhizomelic chondrodysplasia punctata (RCDP), which causes significant physical and neurological delays in children who inherit it. Med-Life Discoveries has received a no objection letter (NOL) from Health Canada to begin a phase […] June 9, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2023 MOSAIC spatial atlas of cancer cells to be created Owkin, NanoString Technologies and cancer research institutions University of Pittsburgh, Gustave Roussy, Lausanne University Hospital, Uniklinikum Erlangen/Friedrich-Alexander- Universität Erlangen-Nürnberg, and Charité – Universitätsmedizin Berlin are launching MOSAIC (Multi Omic Spatial Atlas In Cancer) at the American Society of Clinical Oncology’s annual meeting. MOSAIC is a $50 million project to revolutionize cancer research through the use […] June 9, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2023 Astellas developing new gastric cancer drug Astellas Pharma Inc. has submitted a new drug application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for zolbetuximab. Zolbetuximab is a first-in-class investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive. If approved, […] June 9, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2023 Quell in potential $2B AstraZeneca cell therapy deal Quell Therapeutics Ltd, a developer of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has entered into a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialize autologous, engineered Treg cell therapies for two autoimmune disease indications. “We are extremely pleased to have AstraZeneca on […] June 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2023 Acepodia raises $100M financing to boost cell therapies Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its antibody-cell conjugation (ACC) and allogeneic gamma delta 2 T-cell platforms to address gaps in cancer care, has announced a $100 million Series D financing. The funds will be used to progress the company’s pipeline of enhanced cell therapies for solid tumors and hematologic […] June 8, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2023 Kate Therapeutics launches with $51M to develop genetic medicines for muscle and heart diseases Gene therapy company Kate Therapeutics Inc. (KateTx), has emerged from stealth mode with a $51 million Series A financing. In addition, the company has granted Astellas Pharma Inc. an exclusive, worldwide license to develop, manufacture and commercialize KT430 to treat X-linked myotubular myopathy (XLMTM). There are a large number of genetically defined and complex muscle […] June 8, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email